



## **TCR<sup>2</sup> Therapeutics to Present at the H.C. Wainwright BioConnect Conference**

January 5, 2022

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR<sup>2</sup> Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR<sup>2</sup> Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10<sup>th</sup> at 7:00AM E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company's website at [www.investors.tcr2.com](http://www.investors.tcr2.com). An archived replay will be available for at least 30 days following the presentation.

### **About TCR<sup>2</sup> Therapeutics**

TCR<sup>2</sup> Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC<sup>®</sup>-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR<sup>2</sup>, please visit [www.tcr2.com](http://www.tcr2.com).

### **Investor and Media Contacts:**

#### **TCR<sup>2</sup> Therapeutics**

Carl Mauch  
Director, Investor Relations and Corporate Communications  
(617) 949-5667  
[carl.mauch@tcr2.com](mailto:carl.mauch@tcr2.com)



Source: TCR<sup>2</sup> Therapeutics